Tirzepatide (pre-filed pen)

Specifications Tirzepatide (pre-filed pen):

Company: Hilma Biocare
Active Half-life : approximately 5 days (117–120 hours)
Group: Peptide Hormone
Subgroup: Injection
Dosage: 10 mg
Application (Men): 2,5 to 15 mg
Product pack:  3 ml (Injection Pen)
Content (active): Tirzepatide
Retains water: not recognized
Aromatization: No

Product Description

Tirzepatide is a dual agonist of the GIP and GLP-1 receptors. Tirzepatide is an analogue of gastric inhibitory polypeptide (GIP), a human hormone that stimulates insulin release from the pancreas. Tirzepatide is a linear polypeptide of 39 amino acids, chemically modified by lipidation to improve its cellular uptake and metabolic stability.

Indication

Treatment of type 2 diabetes mellitus and weight loss. Tirzepatide is used to improve glycemic control in combination with diet and exercise.

Mechanism of Action

Tirzepatide has a higher affinity for GIP receptors than for GLP-1 receptors, and this dual agonist action provides a more pronounced reduction in hyperglycemia compared to a selective GLP-1 receptor agonist. Tirzepatide mimics the action of natural GIP on the GIP receptor. At the GLP-1 receptor, tirzepatide preferentially forms cAMP (a messenger involved in the regulation of glycogen, sugar, and lipid metabolism) rather than attracting beta-arrestin. This combination of its preference for the GIP receptor and the specific signaling properties of GLP-1 increases insulin secretion. Tirzepatide increases levels of both adiponectin and adipokine, which are involved in the regulation of both glucose and lipid metabolism, with a maximum increase of 26% from baseline after 26 weeks at a dose of 10 mg.